eMI review

What it is

eMI Aesthetics is a Miami company known for AI simulators that preview cosmetic results, such as fillers or breast augmentation, from a selfie, and it matches users with aesthetic practices. Its GLP-1 weight-loss program adds an AI weight-loss simulator that predicts how you might look at a goal weight and tracks progress. Clinical care comes from the OpenLoop Health network of licensed clinicians, whose intake hosts the program's sign-up. The company says the program is available in all 50 states. Its terms describe services offered with affiliated medical groups and providers, a cash-pay model with no insurance billing, and individual binding arbitration of disputes. It doesn't name its legal entity type, medical director or dispensing pharmacies on the site.

How it works

You start with a secure online form about your health history and goals. If you look eligible, you book a video visit with a licensed provider, who decides whether a GLP-1 is appropriate and which program fits. Medication then ships to your home from U.S.-based pharmacies. The premium program describes regular virtual check-ins every two weeks to adjust your plan. Every plan includes complimentary care coaching: a certified medical assistant meets with you every two weeks and works through a 12-module curriculum covering goal setting, nutrition, sleep and handling side effects. A care app lets you track progress and send medical questions, and you get free access to the AI weight-loss simulator. Two paths are offered: a standard weight-loss program and a lower-dose "longevity" program in 4- or 12-week blocks. The FAQ says the whole process is online, from the health assessment to the prescription and check-ins, with no clinic visit needed. The simulator works from an uploaded photo and a goal weight, and you can use it without taking a GLP-1.

Pricing transparency

eMI's FAQ says the program starts "as low as $179/month". Its medications page lists oral semaglutide and compounded semaglutide injections from $179, compounded tirzepatide from $269, brand-name Zepbound from $1,399 and Ozempic from $1,299. Weight-loss plans come in 4-, 12-, 24- and 52-week lengths, and the longevity plans in 4 or 12 weeks, but the site doesn't show what each length costs or whether the starting figures apply only to the longest plans; that appears after you begin the intake. Its terms say subscriptions renew automatically until you cancel, with the billing cadence and cancellation cutoff, such as 48 hours before renewal, disclosed at checkout. All sales are final except as a refund policy states, and the footer link labeled "Cancellation and Refund Policy" opens the general terms rather than a separate policy. Installment options such as Klarna or Afterpay may be offered, and insurance isn't billed.

Branded vs compounded

eMI lists compounded semaglutide as a weekly injection or an oral form, compounded tirzepatide by injection, lower-dose microdose versions of all three, and brand-name Ozempic and Zepbound. Its pages promise "FDA-approved medications from trusted pharmacies" and its FAQ says compounded versions are produced in FDA-regulated facilities; the compounded drugs themselves are not FDA-approved, and Ozempic is approved for type 2 diabetes rather than weight loss. On its medications page, compounded semaglutide appears under an Ozempic heading and compounded tirzepatide under a Zepbound heading, so read each listing carefully. The pharmacies aren't named, so ask which one will fill your prescription and whether it is a 503A or 503B facility. A search of the FDA warning-letter database under eMI Aesthetics returned no letters, and the site doesn't display a LegitScript seal.

Pros and watch-outs

The evidence behind what eMI prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• What the semaglutide weight-loss trials actually showed

  STEP 1, STEP 4, and SELECT — the efficacy, the rebound, and the cardiovascular signal, read straight from the primary literature.

• Oral semaglutide (Rybelsus): what the PIONEER trials actually showed

  A GLP-1 peptide in a pill is hard to pull off. PIONEER 1, 4, and 6 plus OASIS 1 — read straight from the primary literature.

• “Microdosing” GLP-1 drugs: a trend, not a protocol — what the evidence says

  Sub-therapeutic semaglutide and tirzepatide is spreading fast. The pharmacology is clear, the honest part is clearer: efficacy is dose-related, and no trial has tested intentional microdosing.

How eMI compares

A few alternatives worth a look, depending on what you’re optimizing for.

• yourEra

  A low-cost entry point into compounded GLP-1 treatment

  See yourEra →
• Bodybuilding Health+

  GLP-1 alongside NAD⁺ and sermorelin from a fitness brand

  See Bodybuilding Health+ →
• Henry Meds

  Simple flat-fee compounded access without insurance

  See Henry Meds →

More GLP-1 telehealth reviews: Willow · Eden · WellMedRx · Sprout Health · Wellorithm · TrimRx